These findings lend support to the consideration of early sRT as a viable intervention for patients with negative PSMA PET findings, emphasizing the importance of tailoring treatment approaches based on both PSMA PET results and tumor-specific characteristics. The gene discussed is FOLH1; the disease is neoplasm.